Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857020 | 1.00 | HRH2 (0.53) | HRH2HRH1HTR2ACYP2D6KDM4E | |
| SCHEMBL3838961 | 0.91 | HTR2A (0.47) | HRH2HRH1HTR2ACYP2D6PABPC1 | |
| SCHEMBL7238700 | 0.90 | SLC18A3 (0.51) | HRH2HRH1HTR2ACYP3A4 | |
| SCHEMBL3843208 | 0.90 | SLC18A3 (0.51) | HRH2HRH1HTR2ACYP3A4 | |
| SCHEMBL3839834 | 0.88 | HSD11B1 (0.50) | HRH2HRH1HTR2APABPC1 | |
| SCHEMBL3838969 | 0.87 | PABPC1 (0.45) | HRH2HRH1HTR2ACYP2D6KDM4E | |
| SCHEMBL272157 | 0.83 | ATM (0.64) | CYP3A4ATM | |
| SCHEMBL31404216 | 0.80 | ATM (0.60) | ATM | |
| SCHEMBL30757694 | 0.80 | ATM (0.60) | ATM | |
| SCHEMBL6990678 | 0.80 | SMN1; SMN2 (0.51) | HRH2HRH1HTR2ACYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303488-B1 | PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-6670379-B2 | Inflammatory or allergic conditions, asthma, inhibition of eosinophil activation, conjunctivitis; (1-((R2-Amino-3-pyridin-3-yl-propyl)-piperidin-4-yl)-(4-fluoro-phenyl) -methanone | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | disclosed |
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | CCR1, CCR3, CCR4 | HRH2 95/4885HRH1 64/4885HTR2A 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.